BACKGROUND: We report a prospective multicenter phase II study of haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3. DESIGN AND METHODS: Sixty-one adults with a median age of 46 years (range 19-65 years) have been enrolled. Diagnoses were acute myeloid leukemia (n=38), acute lymphoblastic leukemia (n=8), non-Hodgkin's lymphoma (n=6), myeloma (n=4), chronic myeloid leukemia (n=3), chronic lymphatic leukemia (n=1) and myelodysplastic syndrome (n=1). Patients were considered high risk because of refractory disease (n=18), cytogenetics (n=6), complete remission (≥ 2) (n=9), chemosensitive relapse in partial remission (n=4) or relapse after prior hematopoietic stem cell transplantation (n=15 allogeneic, n=8 autologous, n=1 both). At haploidentical hematopoietic stem cell transplantation, 30 patients were in complete remission and 31 in partial remission. Grafts contained a median of 7.0 × 10(6) (range 3.2-22) CD34(+) cells/kg, 4.2 × 10(4) (range 0.6-44) CD3(+) T cells/kg and 2.7 × 10(7) (range 0.00-37.3) CD56(+) cells/kg. RESULTS: Engraftment was rapid with a median of 12 days to granulocytes more than 0.5 × 10(9)/L (range 9-50 days) and 11 days to platelets more than 20 × 10(9) (range 7-38 days). Incidence of grade IIIV acute graft-versus-host-disease and chronic graft-versus-host-disease was 46% and 18%, respectively. Non-relapse mortality on Day 100 was 23% and 42% at two years. Cumulative incidence of relapse/progression at two years was 31%. Kaplan-Meier estimated 1-year and 2-year overall survival with median follow up of 869 days (range 181-1932) is 41% and 28%, respectively. CONCLUSIONS: This regimen allows successful haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning in high-risk patients lacking a suitable donor. (clinicaltrials.gov identifier:NCT00202917).
BACKGROUND: We report a prospective multicenter phase II study of haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3. DESIGN AND METHODS: Sixty-one adults with a median age of 46 years (range 19-65 years) have been enrolled. Diagnoses were acute myeloid leukemia (n=38), acute lymphoblastic leukemia (n=8), non-Hodgkin's lymphoma (n=6), myeloma (n=4), chronic myeloid leukemia (n=3), chronic lymphatic leukemia (n=1) and myelodysplastic syndrome (n=1). Patients were considered high risk because of refractory disease (n=18), cytogenetics (n=6), complete remission (≥ 2) (n=9), chemosensitive relapse in partial remission (n=4) or relapse after prior hematopoietic stem cell transplantation (n=15 allogeneic, n=8 autologous, n=1 both). At haploidentical hematopoietic stem cell transplantation, 30 patients were in complete remission and 31 in partial remission. Grafts contained a median of 7.0 × 10(6) (range 3.2-22) CD34(+) cells/kg, 4.2 × 10(4) (range 0.6-44) CD3(+) T cells/kg and 2.7 × 10(7) (range 0.00-37.3) CD56(+) cells/kg. RESULTS: Engraftment was rapid with a median of 12 days to granulocytes more than 0.5 × 10(9)/L (range 9-50 days) and 11 days to platelets more than 20 × 10(9) (range 7-38 days). Incidence of grade IIIV acute graft-versus-host-disease and chronic graft-versus-host-disease was 46% and 18%, respectively. Non-relapse mortality on Day 100 was 23% and 42% at two years. Cumulative incidence of relapse/progression at two years was 31%. Kaplan-Meier estimated 1-year and 2-year overall survival with median follow up of 869 days (range 181-1932) is 41% and 28%, respectively. CONCLUSIONS: This regimen allows successful haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning in high-risk patients lacking a suitable donor. (clinicaltrials.gov identifier:NCT00202917).
Authors: P Lang; M Schumm; J Greil; P Bader; T Klingebiel; I Müller; T Feuchtinger; M Pfeiffer; P-G Schlegel; D Niethammer; R Handgretinger Journal: Klin Padiatr Date: 2005 Nov-Dec Impact factor: 1.349
Authors: Sarah Cooley; Valarie McCullar; Rosanna Wangen; Tracy L Bergemann; Stephen Spellman; Daniel J Weisdorf; Jeffrey S Miller Journal: Blood Date: 2005-08-30 Impact factor: 22.113
Authors: M Bornhäuser; C Thiede; C Brendel; G Geissler; U Oelschlägel; A Neubauer; G Ehninger Journal: Transplantation Date: 1999-07-15 Impact factor: 4.939
Authors: M Eyrich; P Lang; S Lal; P Bader; R Handgretinger; T Klingebiel; D Niethammer; P G Schlegel Journal: Br J Haematol Date: 2001-08 Impact factor: 6.998
Authors: M Schumm; P Lang; G Taylor; S Kuçi; T Klingebiel; H J Bühring; A Geiselhart; D Niethammer; R Handgretinger Journal: J Hematother Date: 1999-04
Authors: Wolfgang A Bethge; Matthias Haegele; Christoph Faul; Peter Lang; Michael Schumm; Martin Bornhauser; Rupert Handgretinger; Lothar Kanz Journal: Exp Hematol Date: 2006-12 Impact factor: 3.084
Authors: Mark Cook; David Briggs; Charles Craddock; Premini Mahendra; Donald Milligan; Christopher Fegan; Philip Darbyshire; Sarah Lawson; Elizabeth Boxall; Paul Moss Journal: Blood Date: 2005-10-20 Impact factor: 22.113
Authors: W Arcese; A Picardi; S Santarone; G De Angelis; R Cerretti; L Cudillo; E Pennese; P Bavaro; P Olioso; T Dentamaro; L Cupelli; A Chierichini; A Ferrari; A Mengarelli; M C Tirindelli; M Testi; F Di Piazza; P Di Bartolomeo Journal: Bone Marrow Transplant Date: 2015-06 Impact factor: 5.483
Authors: C Bonini; J Peccatori; M T L Stanghellini; L Vago; A Bondanza; N Cieri; R Greco; M Bernardi; C Corti; G Oliveira; E Zappone; C Traversari; C Bordignon; F Ciceri Journal: Bone Marrow Transplant Date: 2015-06 Impact factor: 5.483
Authors: Johnnie J Orozco; Aimee Kenoyer; Ethan R Balkin; Ted A Gooley; Donald K Hamlin; D Scott Wilbur; Mark D Hylarides; Sofia H L Frost; Raya Mawad; Paul O'Donnell; Brenda M Sandmaier; Ephraim J Fuchs; Leo Luznik; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel Journal: Blood Date: 2015-11-17 Impact factor: 22.113